A Boston federal judge criticized the pleadings in two unusual purported class actions against Genzyme Corp. over its rationing of the drug Fabrazyme, complaining that just one of more than 70 plaintiffs appears to have a valid claim.

The drug treats Fabry Disease, a potentially life-threatening inherited disorder stemming from the buildup of a particular type of fat in the body’s cells.